ASCO25: Pfizer’s Braftovi combo boasts 47% drop in disease progression in mCRC
Phase III progression-free survival data were positive for first-line Braftovi in first-line combination therapy for mCRC.
Phase III progression-free survival data were positive for first-line Braftovi in first-line combination therapy for mCRC.
What's Your Reaction?
